Cover Image
市場調查報告書

青光眼:開發平台分析

Glaucoma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232844
出版日期 內容資訊 英文 298 Pages
訂單完成後即時交付
價格
Back to Top
青光眼:開發平台分析 Glaucoma - Pipeline Review, H2 2016
出版日期: 2016年09月21日 內容資訊: 英文 298 Pages
簡介

本報告提供青光眼的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新新聞及發表的企業和研究機關開發中的治療藥、治療藥評估、後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

青光眼概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

青光眼:企業開發中的治療藥

青光眼:大學/機關研究中的治療藥

青光眼:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

青光眼:企業開發中的產品

青光眼:大學/機關研究中的產品

青光眼的治療藥的開發企業

  • AC Immune SA
  • Acadia Pharmaceuticals Inc.
  • Advanced Refractive Technologies, Inc.
  • Aerie Pharmaceuticals, Inc.
  • Allergan Plc
  • Altacor Limited
  • Amakem NV
  • Amarantus Bioscience Holdings, Inc.
  • Astellas Pharma Inc.
  • AUS Bio Limited
  • Bausch & Lomb Incorporated
  • BioAxone BioSciences, Inc.
  • Bionure Farma, S.L.
  • Caladrius Biosciences, Inc.
  • Can-Fite BioPharma Ltd.
  • Coronis Partners Ltd.
  • D. Western Therapeutics Institute, Inc.
  • Dompe Farmaceutici S.p.A.
  • F. Hoffmann-La Roche Ltd.
  • Gene Signal International SA
  • Gilead Sciences, Inc.
  • Glaukos Corporation
  • GliaCure Inc.
  • Handok Inc.
  • Icon Bioscience, Inc.
  • ID Pharma Co., Ltd.
  • InMed Pharmaceuticals Inc.
  • Inotek Pharmaceuticals Corporation
  • InSite Vision Incorporated
  • Isarna Therapeutics GmbH
  • Kadmon Corporation, LLC
  • Kala Pharmaceuticals, Inc.
  • 興和
  • Kukje Pharmaceutical Industry Co., Ltd.
  • Lee's Pharmaceutical Holdings Limited
  • Lexicon Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Merz Pharma GmbH & Co. KgaA
  • Nemus Bioscience, Inc.
  • Neurotech Pharmaceuticals, Inc.
  • NicOx S.A.
  • NoNO, Inc.
  • Novaliq GmbH
  • Ocular Therapeutix, Inc.
  • Oculis ehf
  • Ohr Pharmaceutical Inc.
  • 小野藥品工業
  • 大塚集團
  • Oxford BioMedica Plc
  • pSivida Corp.
  • Quark Pharmaceuticals, Inc.
  • Quethera Limited
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi
  • 參天製藥
  • 千壽製藥
  • Shire Plc
  • SK Biopharmaceuticals Co., Ltd.
  • Sun Pharma Advanced Research Company Ltd.
  • Sylentis S.A.U.
  • UAB Profarma
  • ViSci Ltd.
  • vTv Therapeutics LLC

青光眼:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

青光眼:最近的開發平台趨勢

青光眼:暫停中的計劃

青光眼:開發中止的產品

青光眼:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8471IDB

Summary

Global Markets Direct's, 'Glaucoma - Pipeline Review, H2 2016', provides an overview of the Glaucoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Glaucoma
  • The report reviews pipeline therapeutics for Glaucoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Glaucoma therapeutics and enlists all their major and minor projects
  • The report assesses Glaucoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Glaucoma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Glaucoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glaucoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Glaucoma Overview
  • Therapeutics Development
  • Glaucoma - Therapeutics under Development by Companies
  • Glaucoma - Therapeutics under Investigation by Universities/Institutes
  • Glaucoma - Pipeline Products Glance
  • Glaucoma - Products under Development by Companies
  • Glaucoma - Products under Investigation by Universities/Institutes
  • Glaucoma - Companies Involved in Therapeutics Development
  • Glaucoma - Therapeutics Assessment
  • Drug Profiles
  • Glaucoma - Dormant Projects
  • Glaucoma - Discontinued Products
  • Glaucoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Glaucoma, H2 2016
  • Number of Products under Development for Glaucoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Glaucoma - Pipeline by AC Immune SA, H2 2016
  • Glaucoma - Pipeline by Acadia Pharmaceuticals Inc., H2 2016
  • Glaucoma - Pipeline by Advanced Refractive Technologies, Inc., H2 2016
  • Glaucoma - Pipeline by Aerie Pharmaceuticals, Inc., H2 2016
  • Glaucoma - Pipeline by Allergan Plc, H2 2016
  • Glaucoma - Pipeline by Altacor Limited, H2 2016
  • Glaucoma - Pipeline by Amakem NV, H2 2016
  • Glaucoma - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
  • Glaucoma - Pipeline by Amgen Inc., H2 2016
  • Glaucoma - Pipeline by Astellas Pharma Inc., H2 2016
  • Glaucoma - Pipeline by Bausch & Lomb Incorporated, H2 2016
  • Glaucoma - Pipeline by BioAxone BioSciences, Inc., H2 2016
  • Glaucoma - Pipeline by Bionure Farma, S.L., H2 2016
  • Glaucoma - Pipeline by Coronis Partners Ltd., H2 2016
  • Glaucoma - Pipeline by D. Western Therapeutics Institute, Inc., H2 2016
  • Glaucoma - Pipeline by Dompe Farmaceutici S.p.A., H2 2016
  • Glaucoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Glaucoma - Pipeline by Gilead Sciences, Inc., H2 2016
  • Glaucoma - Pipeline by Glaukos Corporation, H2 2016
  • Glaucoma - Pipeline by Graybug Vision Inc, H2 2016
  • Glaucoma - Pipeline by Handok Inc., H2 2016
  • Glaucoma - Pipeline by HitGen LTD, H2 2016
  • Glaucoma - Pipeline by Icon Bioscience, Inc., H2 2016
  • Glaucoma - Pipeline by ID Pharma Co., Ltd., H2 2016
  • Glaucoma - Pipeline by InMed Pharmaceuticals Inc., H2 2016
  • Glaucoma - Pipeline by Inotek Pharmaceuticals Corporation, H2 2016
  • Glaucoma - Pipeline by InSite Vision Incorporated, H2 2016
  • Glaucoma - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016
  • Glaucoma - Pipeline by Isarna Therapeutics GmbH, H2 2016
  • Glaucoma - Pipeline by Kala Pharmaceuticals, Inc., H2 2016
  • Glaucoma - Pipeline by Kowa Company, Ltd., H2 2016
  • Glaucoma - Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H2 2016
  • Glaucoma - Pipeline by Laboratoires Thea S.A., H2 2016
  • Glaucoma - Pipeline by Laboratorios Sophia S.A. de C.V., H2 2016
  • Glaucoma - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
  • Glaucoma - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016
  • Glaucoma - Pipeline by Merck & Co., Inc., H2 2016
  • Glaucoma - Pipeline by Nemus Bioscience, Inc., H2 2016
  • Glaucoma - Pipeline by NicOx S.A., H2 2016
  • Glaucoma - Pipeline by NoNO, Inc., H2 2016
  • Glaucoma - Pipeline by Novaliq GmbH, H2 2016
  • Glaucoma - Pipeline by Ocular Therapeutix, Inc., H2 2016
  • Glaucoma - Pipeline by Oculis ehf, H2 2016
  • Glaucoma - Pipeline by Ohr Pharmaceutical Inc., H2 2016
  • Glaucoma - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Glaucoma - Pipeline by Oxford BioMedica Plc, H2 2016
  • Glaucoma - Pipeline by Profarma, H2 2016
  • Glaucoma - Pipeline by pSivida Corp., H2 2016
  • Glaucoma - Pipeline by Quark Pharmaceuticals, Inc., H2 2016
  • Glaucoma - Pipeline by Quethera Limited, H2 2016
  • Glaucoma - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • Glaucoma - Pipeline by Sanofi, H2 2016
  • Glaucoma - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016
  • Glaucoma - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2016
  • Glaucoma - Pipeline by Shire Plc, H2 2016
  • Glaucoma - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
  • Glaucoma - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
  • Glaucoma - Pipeline by Sylentis S.A.U., H2 2016
  • Glaucoma - Pipeline by ViSci Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Glaucoma - Dormant Projects, H2 2016
  • Glaucoma - Dormant Projects (Contd..1), H2 2016
  • Glaucoma - Dormant Projects (Contd..2), H2 2016
  • Glaucoma - Dormant Projects (Contd..3), H2 2016
  • Glaucoma - Dormant Projects (Contd..4), H2 2016
  • Glaucoma - Dormant Projects (Contd..5), H2 2016
  • Glaucoma - Dormant Projects (Contd..6), H2 2016
  • Glaucoma - Dormant Projects (Contd..7), H2 2016
  • Glaucoma - Discontinued Products, H2 2016
  • Glaucoma - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Glaucoma, H2 2016
  • Number of Products under Development for Glaucoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top